NOW PLAYING
(NewsNation) — A recent trial suggests apitegromab, when used alongside tirzepatide, may help preserve lean body mass while supporting overall weight loss.
The analysis, published in Nature, found apitegromab — a monoclonal antibody — targets myostatin to help maintain muscle mass when combined with the GLP-1 medication. Apitegromab works by inhibiting the activation of myostatin, a protein that limits skeletal muscle growth, according to Medscape.
“Results from EMBRAZE demonstrate clinical proof of concept for a highly selective anti-myostatin antibody to preserve lean mass with tirzepatide therapy,” the study authors said.
Researchers studied 102 adults with overweight or obesity over 24 weeks. Participants received tirzepatide combined with either apitegromab or a placebo.
The results showed those receiving apitegromab lost less lean mass compared with participants given a placebo. Researchers said about 85% of total weight loss among the apitegromab group came from fat.
Adverse events were reported in 76% of participants receiving apitegromab and 71% of those receiving a placebo.
The study excluded individuals with conditions such as diabetes, heart disease, stroke, vascular disorders or active cancer.
Add as preferred source on Google TagsCopyright 2026 Nexstar Media Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Comments: Link copiedMore Healthcare News
See All
Healthcare US’s fertility rate has declined since 2007. It’s even worse in these states by Addy Bink 51 minutes ago Healthcare / 51 minutes ago 
